Current Role and Responsibilities
Jay G. Wohlgemuth, M.D., served as Senior Vice President, Research & Development (R&D), Medical and Chief Medical Officer (CMO) at Quest Diagnostics until late 2023, holding these key executive roles for approximately 14 years. Within Quest Diagnostics, he led the company’s scientific innovation, clinical diagnostics research, and medical strategy initiatives. His responsibilities notably included oversight of Employer Population Health services and guiding Quest’s response to major public health challenges such as the COVID-19 pandemic and opioid addiction trends.
He was prominently involved in advancing Quest Diagnostics’ capabilities in diagnostic testing, molecular and precision medicine, virtual care, and digital health platforms. Notably, as CMO and SVP of R&D, Dr. Wohlgemuth was instrumental in launching and expanding COVID-19 diagnostic testing programs, including FDA-authorized specimen pooling and consumer-initiated antibody tests. He also led efforts in emerging infectious disease diagnostics, exemplified by the launch of monkeypox virus testing.
Dr. Wohlgemuth oversaw partnerships and innovation strategies, exemplified by his current role as Managing Partner at Trusted Health Advisors, supporting next-generation diagnostic product market strategies (e.g., for Mainz Biomed’s early colorectal cancer diagnostics). His expertise facilitated collaboration between Quest and other health technology stakeholders to broaden the availability and adoption of advanced testing services.
Professional Background and Education
- Bachelor’s degree in Biology – Harvard College
- Medical degree (M.D.) – Stanford University School of Medicine
- Fellowship in cardiovascular medicine at Stanford Medical School
- Previously held senior leadership positions at leading organizations:
- Director, Clinical Diagnostics for Immunology, Tissue Growth, and Repair at Genentech
- Vice President, Research and Development at VIA Pharmaceuticals
- Co-founder and Chief Medical Officer at molecular diagnostics company XDx (recognized as a Technology Pioneer by the World Economic Forum in 2005 for his contributions to molecular diagnostics)
Dr. Wohlgemuth’s academic and industry experience combines clinical expertise, cutting-edge diagnostics research, and health innovation, positioning him as a thought leader in personalized and precision medicine.
Contributions and Innovations
- Oversaw Quest Diagnostics’ rapid deployment and scaling of COVID-19 diagnostic testing, achieving a national laboratory capacity able to report a vast majority of test results within one day.
- Played a key role in driving consumer-directed diagnostic services via QuestDirect™, enabling at-home access to antibody testing and biomarker analysis.
- Led new diagnostic initiatives focused on population health management, including diabetes cost reduction programs demonstrated to reduce drug costs by 18% for consistent program participants.
- Featured speaker and thought leader at multiple industry conferences focused on molecular and precision medicine, diagnostics innovation, and health care workforce well-being.
- Cited in peer-reviewed publications related to diagnostic testing methodologies, including research on SARS-CoV-2 serology and lipoprotein profiling.
Quest Diagnostics Corporate Context
- Quest Diagnostics (NYSE: DGX) is a national reference laboratory with revenue exceeding $9 billion in 2023 and a market capitalization around $18 billion.
- The company serves one out of every three adults in the United States through a broad network of testing services.
- Quest Diagnostics has emphasized innovation in diagnostic testing, including at-home collection services, biomarker testing, infectious disease surveillance, and employer population health programs under Dr. Wohlgemuth’s leadership.
- The company regularly publishes a Corporate Responsibility Report, citing Jay Wohlgemuth’s leadership in medical and R&D for new diagnostic initiatives and public/private collaborations against COVID-19 and other health challenges.
Recent Transition and Current Activities
- As of December 2023, Quest Diagnostics appointed Dr. Yuri Fesko as Senior Vice President and Chief Medical Officer following Dr. Wohlgemuth’s departure from these roles.
- Jay Wohlgemuth currently serves as Managing Partner of Trusted Health Advisors, a consultancy focused on advising diagnostic and health innovation companies, leveraging his extensive experience at Quest.
- He continues to be engaged in shaping market strategies and diagnostic product adoption for innovative healthcare solutions, including collaborations with Mainz Biomed.
Professional Affiliations and Public Engagements
- Former Board Member of the Personalized Medicine Coalition, actively involved in policy and industry leadership to advance precision medicine.
- Participation in industry conferences such as the Molecular & Precision Med Tri-Conference where he presented on diagnostics innovation and population health.
- Contributed to media statements and corporate communications regarding pandemic response and diagnostic testing capabilities at Quest Diagnostics.
Jay Wohlgemuth, M.D. is a senior healthcare executive and physician-scientist with a proven track record of innovation and leadership in the diagnostics industry. His extensive tenure at Quest Diagnostics, culminating as Senior Vice President of R&D and Chief Medical Officer, underscore his role in integrating scientific advances with scalable healthcare services, particularly in response to public health emergencies and chronic disease management. His transition to consultancy through Trusted Health Advisors positions him as an influential advisor in advancing next-generation diagnostic products to market.
